Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$0.89 -3.2%	$1.08	$0.85 ▼ $4.00	$28.70M	0.22	30,341 shs	71,670 shs
CLSD Clearside Biomedical	$0.41 -0.5%	$0.61	$0.29 ▼ $1.65	$31.80M	2.08	1.84 million shs	634,595 shs
MURA Mural Oncology	$2.07 -0.7%	$2.27	$0.95 ▼ $4.74	$35.77M	3	1.98 million shs	414,101 shs
PRTG Portage Biotech	$8.11 -11.0%	$6.62	$2.81 ▼ $23.01	$8.51M	0.24	585,268 shs	24,542 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	-8.75%	-16.61%	-27.73%	-76.00%
CLSD Clearside Biomedical	0.00%	-3.74%	-18.10%	-52.82%	-60.08%
MURA Mural Oncology	0.00%	+18.18%	-14.05%	-24.36%	-39.88%
PRTG Portage Biotech	0.00%	+4.95%	+58.99%	+15.46%	+51.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	2.3186 of 5 stars	3.5	3.0	0.6	3.3	0.0
CLSD Clearside Biomedical	1.8293 of 5 stars	4.1	3.0	0.6	0.0	0.0
MURA Mural Oncology	2.9402 of 5 stars	3.3	3.0	1.8	2.5	1.3
PRTG Portage Biotech	0.3192 of 5 stars	0.0	5.0	0.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	460.54% Upside
CLSD Clearside Biomedical	2.17	Hold	$4.20	937.04% Upside
MURA Mural Oncology	2.50	Moderate Buy	$12.00	481.11% Upside
PRTG Portage Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRTG, AKTX, CLSD, and MURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
CLSD Clearside Biomedical	$4.17M	7.63	N/A	N/A	($0.51) per share	-0.79
MURA Mural Oncology	N/A	N/A	N/A	N/A	$8.22 per share	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	($0.79) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-78.03%	-31.62%	9/25/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	11/12/2025 (Estimated)
PRTG Portage Biotech	-$6.77M	-$41.65	N/A	∞	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)

Latest PRTG, AKTX, CLSD, and MURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
PRTG Portage Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.19	0.19
CLSD Clearside Biomedical	N/A	3.87	3.87
MURA Mural Oncology	N/A	2.87	2.87
PRTG Portage Biotech	N/A	2.02	2.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
CLSD Clearside Biomedical	18.75%
MURA Mural Oncology	80.21%
PRTG Portage Biotech	13.36%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
CLSD Clearside Biomedical	6.70%
MURA Mural Oncology	2.20%
PRTG Portage Biotech	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable
PRTG Portage Biotech	6	1.05 million	N/A	Optionable

PRTG, AKTX, CLSD, and MURA Headlines

Recent News About These Companies

Portage Biotech (NASDAQ:PRTG) Stock Price Down 1.4% - Time to Sell?

August 16, 2025 | americanbankingnews.com

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

July 25, 2025 | globenewswire.com

Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | Nasdaq

June 27, 2025 | nasdaq.com

PRTG Portage Biotech Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Portage Biotech Inc. (PRTG) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Portage Biotech Regains Nasdaq Compliance

June 25, 2025 | tipranks.com

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

June 25, 2025 | globenewswire.com

Portage Biotech Inc. (PRTG) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Portage Biotech acquires stake in Compedica for $5 million

June 10, 2025 | investing.com

Portage Biotech and Compedica Forge Strategic Alliance with Stock Exchange

June 9, 2025 | tipranks.com

Portage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity Investment

June 9, 2025 | quiverquant.comQ

Portage Biotech and Compedica Stock-for-Stock Exchange

June 9, 2025 | globenewswire.com

Portage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human Trial

April 28, 2025 | marketwatch.com

Portage Biotech stock soars on promising preclinical results

April 28, 2025 | za.investing.com

Portage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More Bullish

April 28, 2025 | msn.com

Portage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025

April 28, 2025 | quiverquant.comQ

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

April 28, 2025 | globenewswire.com

Insider Stock Buying Reaches US$2.15m On Portage Biotech

April 26, 2025 | finance.yahoo.com

Portage Biotech Inc. Common Stock (PRTG) Pre-Market

March 30, 2025 | nasdaq.com

Portage Biotech presents preclinical data for PORT-7

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTG, AKTX, CLSD, and MURA Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$0.89 -0.03 (-3.20%)

As of 03:30 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Clearside Biomedical NASDAQ:CLSD

$0.40 0.00 (-0.54%)

As of 03:33 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Mural Oncology NASDAQ:MURA

$2.06 -0.02 (-0.72%)

As of 03:34 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Portage Biotech NASDAQ:PRTG

$8.11 -1.00 (-11.02%)

As of 03:30 PM Eastern

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time